e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
e-therapeutics has announced plans to present new preclinical data for ETX-148 at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in February 2025. The presentation will showcase the efficacy and safety results of ETX-148 in murine models of haemophilia A and B. ETX-148, which is being developed for treating bleeding disorders, is currently in IND-enabling studies, with an IND submission planned for 2026.
The oral presentation, numbered OR10, will take place during the SLAM session on February 7th, 2025, at EAHAD 2025, which runs from February 4th to 7th.
e-therapeutics ha annunciato piani per presentare nuovi dati preclinici per ETX-148 al Congresso Annuale dell'Associazione Europea per l'Emofilia e i Disturbi Affini (EAHAD) nel febbraio 2025. La presentazione metterà in luce i risultati di efficacia e sicurezza di ETX-148 in modelli murini di emofilia A e B. ETX-148, che è in fase di sviluppo per il trattamento dei disturbi emorragici, è attualmente in studi di abilitazione IND, con una sottomissione IND prevista per il 2026.
La presentazione orale, numero OR10, avrà luogo durante la sessione SLAM il 7 febbraio 2025, all'EAHAD 2025, che si svolge dal 4 al 7 febbraio.
e-therapeutics ha anunciado planes para presentar nuevos datos preclínicos para ETX-148 en el Congreso Anual de la Asociación Europea de Hemofilia y Trastornos Afines (EAHAD) en febrero de 2025. La presentación mostrará los resultados de eficacia y seguridad de ETX-148 en modelos murinos de hemofilia A y B. ETX-148, que se está desarrollando para el tratamiento de trastornos hemorrágicos, se encuentra actualmente en estudios que habilitan el IND, con una presentación de IND prevista para 2026.
La presentación oral, número OR10, tendrá lugar durante la sesión SLAM el 7 de febrero de 2025, en EAHAD 2025, que se llevará a cabo del 4 al 7 de febrero.
e-therapeutics는 2025년 2월 유럽 혈우병 및 관련 질환 협회(EAHAD) 연례 대회에서 ETX-148에 대한 새로운 전임상 데이터를 발표할 계획을 발표했습니다. 이번 발표에서는 A형 및 B형 혈우병의 마우스 모델에서의 ETX-148의 효능과 안전성 결과를 보여줄 것입니다. ETX-148은 출혈 장애 치료를 위해 개발 중이며 현재 IND 승인 준비 연구 중이며, 2026년 출시를 계획하고 있습니다.
OR10으로 번호가 매겨진 구두 발표는 2025년 2월 7일 SLAM 세션 중에 개최되며, EAHAD 2025는 2월 4일부터 7일까지 진행됩니다.
e-therapeutics a annoncé des plans pour présenter de nouvelles données précliniques pour ETX-148 lors du Congrès Annuel de l'Association Européenne de la Hémophilie et des Troubles Associés (EAHAD) en février 2025. La présentation mettra en avant les résultats d'efficacité et de sécurité d'ETX-148 dans des modèles murins de l'hémophilie A et B. ETX-148, qui est en cours de développement pour traiter les troubles de la coagulation, est actuellement dans des études d'habilitation IND, avec une soumission IND prévue pour 2026.
La présentation orale, numérotée OR10, aura lieu pendant la session SLAM le 7 février 2025, lors de l'EAHAD 2025, qui se déroulera du 4 au 7 février.
e-therapeutics hat Pläne angekündigt, neue präklinische Daten für ETX-148 auf dem Jahreskongress der Europäischen Vereinigung für Hämophilie und verwandte Störungen (EAHAD) im Februar 2025 vorzustellen. Die Präsentation wird die Wirksamkeits- und Sicherheitsresultate von ETX-148 in mausmodellen von Hämophilie A und B vorstellen. ETX-148, das zur Behandlung von Blutungsstörungen entwickelt wird, befindet sich derzeit in IND-erlaubenden Studien, mit einer IND-Einreichung, die für 2026 geplant ist.
Die mündliche Präsentation mit der Nummer OR10 findet während der SLAM-Session am 7. Februar 2025 auf der EAHAD 2025 statt, die vom 4. bis 7. Februar läuft.
- ETX-148 is progressing through IND-enabling studies
- Company has preclinical data ready for presentation at major industry conference
- IND submission not expected until 2026, indicating lengthy development timeline ahead
LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressing through IND-enabling studies, with an IND submission anticipated during 2026.
Presentation Details
Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B
Format: Oral Presentation
Presentation Number: OR10
Date: 7th February 2025
Session: SLAM
About e-therapeutics plc
e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover and develop life-transforming medicines. ETX's proprietary RNAi chemistry platform, GalOmic™, enables generation of specific, potent, and durable siRNA therapeutics for effective silencing of novel gene targets in hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. HepNet™ encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design. The Company has specialist expertise and a robust position in applying computation to biology. Its computational approaches have been extensively validated through generation of data from pipeline programs and successful drug discovery collaborations with biopharma companies, such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.
Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need. The Company has generated positive proof-of-concept data on preclinical assets in metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia, heart failure, and cardiometabolic disease, further validating its computationally enhanced approach to research and development. ETX is currently progressing its GalOmic™ therapies towards the clinic with its most developed assets, ETX-312 for MASH, ETX-148 for bleeding disorders, and ETX-407 for dry AMD, at the IND-enabling stage.
Press Contact
press@etherapeutics.co.uk
Investor Relations Contact
investorrelations@etherapeutics.co.uk
FAQ
What is the current development stage of ETX-148 (ETXPF)?
What conditions is ETX-148 (ETXPF) being developed to treat?
When will e-therapeutics present ETX-148 preclinical data at EAHAD 2025?
What type of data will be presented for ETX-148 (ETXPF) at EAHAD 2025?
